The countdown to the domestic entry of an insulin decreasing the risk of hypoglycemia, pre-noticing a war of nerves
As the countdown has begun to the domestic launch of the next-generation basal insulin diabetes treatment having low risk of hypoglycemia, the markets concerned has shown high interests.
Recently, the Novo Nordisk’s next-generation basal insulin ‘Tresiba FlexTouch Inj.(generic name: insulin degl...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
